Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Sanjiu Medical & Pharmaceutical Company Limited, a Shenzhen-listed subsidiary 63.22% owned by China Resources Pharmaceutical Group, reported strong balance sheet growth for 2025, with total assets rising 46.71% to about RMB58.8 billion and net assets attributable to shareholders increasing 11.40% to roughly RMB22.2 billion. The results underline the company’s expanding scale in China’s pharmaceutical sector and its role as a key profit contributor within the parent group.
For the year ended 31 December 2025, CR Sanjiu’s revenue grew 14.43% to about RMB31.6 billion, while net profit attributable to shareholders inched up 1.58% to approximately RMB3.42 billion, and recurring profit growth remained modest. Operating cash flow improved 25.23% to around RMB5.51 billion, and the board proposed raising the cash dividend to RMB5.90 per 10 shares after an earlier RMB4.50 payout in 2025, signaling continued shareholder returns despite a slight decline in weighted average return on net assets to 16.07%.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a Hong Kong–incorporated healthcare conglomerate operating through subsidiaries such as China Resources Sanjiu Medical & Pharmaceutical Company Limited in Mainland China. CR Sanjiu, listed on the Shenzhen Stock Exchange, focuses on the manufacture and sale of pharmaceutical products and related medical goods, serving the Chinese healthcare and consumer medicine markets.
Average Trading Volume: 9,663,369
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.15B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.